Research Article

PET Imaging of FSHR Expression in Tumors with 68Ga-Labeled FSH1 Peptide

Donghui Pan,1 Guifeng Liu,2 Yuping Xu,1,3 Yanting Wang,4 Yuanyuan Yue,4 Lizhen Wang,1 Junjie Yan,1 Xinyu Wang,1 Runlin Yang,1 and Min Yang1,3

1Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063, China
2Department of Radiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China
3Nanjing Medical University, Nanjing, Jiangsu 210029, China
4Zhengzhou University, Zhengzhou, Henan 450001, China

Correspondence should be addressed to Min Yang; yangmin@jsinm.org

Received 29 March 2017; Revised 7 July 2017; Accepted 25 July 2017; Published 23 August 2017

Academic Editor: Shengxian Rao

Copyright © 2017 Donghui Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

FSHR is an appealing target for cancer theranostics. Radiolabeled FSH1 and its derivatives have shown potential to in vivo detect FSHR expression. However, moderate labeling yields (∼50% nondecay-corrected) may partially limit their wide use. 68Ga is an excellent PET nuclide due to availability, nearly quantitative reaction, and short physical half-life. In this study, 68Ga-labeled FSH1 peptide was developed for imaging of FSHR in cancers. In vitro studies and MicroPET imaging were performed in PC-3 prostate tumor model. [68Ga]Ga-NOTA-MAL-FSH1 can be produced within 20 min with 93.2 ± 2.1% yield and the radiochemical purity was greater than 95%. It showed that [68Ga]Ga-NOTA-MAL-FSH1 possessed FSHR binding affinities. The tracer was stable in PBS and human serum for at least 2 hours. MicroPET imaging revealed that the PC-3 xenografts were clearly visualized and the tumor uptakes were 1.87 ± 0.10, 1.26 ± 0.06, and 0.71 ± 0.10 %ID/g at 0.5, 1h, and 2 h postinjection. The corresponding tumor to blood and tumor to muscle ratios were 1.77 ± 0.70, 7.94 ± 1.35, and 10.37 ± 1.16 and 7.42 ± 0.46, 26.13 ± 2.99, and 36.40 ± 2.54, respectively. FSHR binding specificity was also demonstrated by reduced tumor uptake of [68Ga]Ga-NOTA-MAL-FSH1 after coinjecting excess unlabeled FSH1 peptide. The favorable characteristics of [68Ga]Ga-NOTA-MAL-FSH1 such as convenient synthesis and specific tumor uptake warrant its further investigation for FSHR expression imaging.

1. Introduction

Follicle-stimulating hormone (FSH) is a central hormone in mammalian reproductive biology. It promotes the mature spermatogenesis for men and follicular maturation for women, respectively. FSH receptor (FSHR) is a glycosylated transmembrane protein belonging to the family of G-protein-coupled receptors. In adult humans and animals, low levels of FSHR were expressed only in endothelial cells of ovary and testis [1–4].

Immunostaining showed that FSHR was overexpressed in the vasculatures of various solid tumors including prostate, breast, lung, and ovarian cancer. On the contrary, healthy and nonmalignant inflammatory tissues were always FSHR negative [5]. These findings imply that the receptor may be a target for cancer detection and image guided cancer surgery. Moreover, the expression level of FSHR correlates strongly with the response of tumors to antiangiogenic therapies. One clinical study in patients found that the FSHR levels in the primary tumors correlated well with the response to antiangiogenic tyrosine kinase inhibitors (sunitinib) [6]. The percentage of FSHR stained vessels of the responsive patients (∼60%) was significantly higher than those in the stable or nonresponsive group (∼10% and ∼7%, resp.). These characteristics render FSHR an attractive choice for tumor theranostics. Using the FSHR-targeting strategy, paclitaxel attached to FSH peptide was loaded into nanoparticles and the compound displayed antitumor effects [7]. Meanwhile,
a nanographene oxide conjugated to a monoclonal antibody against FSHR was successfully developed for targeting delivery of therapeutics [8].

Besides therapy, noninvasive imaging of FSHR is of benefit to monitor biochemical changes and target abundance within a testing subject. Radiolabeled peptides toward receptors have attracted considerable interest for cancer imaging due to fast clearance, high specificity, excellent tissue penetration, and low immunogenicity [9–13]. Preliminary studies revealed that $^{18}$FAl labeled FSH1 and its derivatives (FSH2) possessed FSHR binding specificity and might be potential probes to in vivo detect FSHR expression [13, 14]. However, moderate labeling yields (∼50% nondecay-corrected) may partially limit their wide use.

Compared with $^{18}$F, a metallic positron emitter, $^{68}$Ga, can be conveniently obtained from an in-house $^{68}$Ge/$^{68}$Ga generator and independent of an onsite cyclotron. With a half-life of 68 min, it is also suitable for the pharmacokinetics of many peptides. In addition, biomolecules can be labeled with $^{68}$Ga by nearly quantitative reaction with macrocyclic chelators. It allows possible kit formulation and accelerated the application of the probes [15].

Previous studies showed that the uptake of $^{18}$FAl labeled FSH1 in FSHR positive PC-3 xenograft was significantly higher than those of FSH2 counterpart at 1 h postinjection ($2.64 \pm 0.25\%$ ID/g versus $1.88 \pm 0.02\%$ ID/g, resp.). FSH1 peptide may be more suitable for tumor imaging than FSH2 [13, 14]. In this study, FSH1 conjugated to maleimide-NOTA, NOTA-MAL-FSH1, was labeled with $^{68}$Ga (Figure 1). The in vitro affinity and the in vivo tumor targeting properties of $[^{68}\text{Ga}]$ Ga-NOTA-MAL-FSH1 were also determined in PC-3 tumor models.

2. Materials and Methods

All commercial reagents were of analytical grade. FSH1 peptide was custom made by Apeptide Co., Ltd., (Shanghai, China). NOTA-MAL-FSH1 was synthesized according to the literature and the purity was greater than 95% [13].
The conditions for HPLC system are as follows [16]: A Waters high-performance liquid chromatography (HPLC) system with a Waters 2998 photodiode array detector (PDA) and a preparative C18 HPLC column (5 µm, 250 × 10 mm, Phenomenex) was used for peptide conjugated purification. The flow is 5 ml/min, and the mobile phase changed from 95% solvent A (0.1% trifluoroacetic acid in water) and 5% solvent B (0.1% trifluoroacetic acid in acetonitrile) (0–2 min) to 35% solvent A and 65% solvent B at 35 min. The UV absorbance was monitored at 218 nm.

The purities of compounds were analyzed by RP-HPLC on a Waters Breeze system equipped with a Radiomatic 610TR flow scintillation analyzer (PerkinElmer) and a Waters Brezee system equipped with a Radioactivity sample injection. The flow is 5 ml/min with the following buffer system: buffer 𝐴 = acid (TFA) in acetonitrile (ACN); and a gradient of 95% buffer 𝐵 = trifluoroacetic acid in water; buffer 𝑆 = solvent (ACN); and a gradient of 95% buffer 𝑆 at 0–2 min to 35% buffer 𝐴 at 35 min.

The HPLC chromatogram and MS spectrum of NOTA-MAL-FSH1 were listed in Figure 2. MS measured m/z 2968.5 for [M + H]+. MAL-FSH1 were listed in Figure 2. MS measured m/z = 2968.1 [13]; [68Ga] GaCl₃ was eluted from a 68Ge/68Ga-generator (ITG, Germany) with 0.05 M HCl. The PC-3 human prostate cancer cell line was purchased from Cell Bank of Shanghai Institutes for Biological Sciences.

2.1. Preparation of 68Ga-NOTA-MAL-FSH1. The fresh [68Ga] GaCl₃ (185 MBq) was added to 300 µL 1 M HEPES buffer and followed 20 µg of NOTA-MAL-FSH1 (6.7 nmol) in 10 µL 0.2 M sodium acetate buffer (pH = 4). The mixture was incubated at 100°C for 10 min. After being diluted with 10 ml of deionized water, the complex was loaded into a Varian BOND ELUT C18 column. The labeled peptide was eluted with 200 µL 10 mM HCl in ethanol. The product was reconstituted in 3 ml saline and passed through a 0.22 µm Millipore filter into a sterile vial. Radiochemical purity was checked with the HPLC system. The retention time for 68Ga-NOTA-MAL-FSH1 was 14.2 min (Figure 3(a)).

2.2. Octanol/PBS Partition Coefficient. To an Eppendorf tube filled with 0.5 ml of the radiolabeled peptide (10 µL, 370 KBq) in phosphate-buffered saline (pH 7.4), 0.5 ml of octanol was added. After stirring for 2 min at room temperature, the two layers were separated by centrifugation. Radioactivity in 100 µL of each layer was measured in a γ-counter (Perkin-Elmer), and log D values were calculated [17]. Experiments were performed in triplicate.

2.3. Stability Studies. 10 µL 370 KBq [68Ga] Ga-NOTA-MAL-FSH1 in saline was incubated in 200 µL PBS or 200 µL human serum for 30, 60, and 120 min at 37°C, respectively. The stability of the labeled peptide in PBS was determined by directly injecting an aliquot of the solution into the HPLC at the preselected time points.

The serum was first mixed with 200 µL acetonitrile to precipitate the proteins. Subsequently, after centrifugation, supernatant was collected and analyzed by radio-HPLC [18]. Protein-binding fraction was calculated by dividing the radioactivity of the precipitation layer by the total activity used.

2.4. Cell Lines and Animal Models. PC-3 cells were cultured and grown in F-12 nutrient (Thermo Fisher) mixture supplemented with 10% (v/v) fetal bovine serum at 37°C in an atmosphere containing 5% CO₂.

The PC-3 tumor model was generated by subcutaneous injection of 5 × 10⁶ cells into the right front flank of male athymic nude mice (4 weeks old, SLAC Laboratory Animal Co., Ltd., China).

The mice were used for MicroPET studies when the tumor volume reached 100–300 mm³, which took about 2 weeks. The animal experiments were conducted in compliance with the national regulations and approved by local animal welfare committee.

2.5. Competitive Cell-Binding Assay. To obtain a homogenous mixture, equivalent of 68Ga-NOTA-MAL-FSH1 and the final solution incubated again for 10 min. Binding affinities toward the FSHR for 68Ga-NOTA-MAL-FSH1 were determined in a competitive binding assay on PC-3 tumor cells using FSH1 as a receptor ligand [19]. PC-3 cells in 6-well plates (2 × 10⁵ cells per well) were cultured until confluency. On the day of assay, cells were washed with binding buffer (RPMI, 0.5% bovine serum albumin). A range of 1 to 5000 nM FSH1 in binding buffer and 370 KBq [68Ga] Ga-NOTA-MAL-FSH1 were added to each well. After incubating at 37°C for 2 h, medium was removed. Then, cells were washed with binding buffer and extracted from the wells by 0.1 M NaOH. Cell-associated radioactivity was determined in a γ-counter (PerkinElmer). Experiments were performed in triplicate. Inhibitory concentration of 50% (IC50) values was determined by GraphPad Prism software (version 5.0).

2.6. Cell Uptakes. PC-3 cells were suspended in 500 µL RPMI 1640 and seeded in 24-well tissue culture plates (1 × 10⁵ cells per well) for overnight incubation. After washing with PBS, the cells were incubated with 370 KBq [68Ga] Ga-NOTA-MAL-FSH1 in the presence or absence of unlabeled FSH1 (to a final concentration of 1 µM) at 37°C for 15, 30, 60, and 120 min, respectively. The cells were washed 3 times with ice-cold PBS and lysed in 0.5 ml of 1.0 M NaOH. The remaining radioactivity was measured in the γ-counter. Cell uptakes were expressed as the percentage of added radioactive dose (% AD). Experiments were performed in triplicate.

2.7. MicroPET Imaging. Mice was injected intravenously with 100 µL 3.7 MBq [68Ga] Ga-NOTA-MAL-FSH1 in saline under isoflurane anesthesia and subjected to MicroPET imaging. The breathing and body temperature of the mice were monitored by BioVet CTI system (M2M Imaging Corp.). For the blocking experiment, unlabeled peptide (10 mg/kg body weight) and 3.7 MBq [68Ga] Ga-NOTA-MAL-FSH1 were coinjected into five mice. Static PET images were acquired for 5 min using an Inveon MicroPET/CT scanner (Siemens Medical Solutions) at 30 min, 1 h, and 2 h postinjection. The
quantification analysis of PET images was performed using the same method as previously reported [13].

2.8. Biodistribution Studies. A number of twenty tumor bearing mice were euthanized with isoflurane (inhalation excess) and dissected at 0.5 h, 1 h, and 2 h (5 mice per time-point) after administrating 740 KBq $^{68}$Ga-Ga-NOTA-MAL-FSH1. To determine the specific uptake, mice were coinjected with the probe with 100 μg of unmodified peptide and sacrificed at 1 h p.i. Normal organs and tumors were collected and weighed. The radioactivity was measured by the $\gamma$-counter and the percentage of injected dose per gram of tissue (% ID/g) was determined.

2.9. Statistical Analysis. Statistical analyses were performed using GraphPad Prism (version 5.0). Data were analyzed
3. Results

3.1. Chemistry and Radiochemistry. The labeling was performed within 20 min, with a decay-corrected yield of 93.2 ± 2.1% (n = 5) and a radiochemical purity of more than 95%. The specific activity was determined to be at least 25 GBq/μmol.

3.2. In Vitro Characterization. The in vitro stability of the $^{68}$Ga labeled tracer was evaluated by incubating in PBS or human serum at 37°C, respectively. Protein-binding fraction was determined to be 16.5 ± 2.5%. The probe displayed high in vitro stability and showed no degradation products or release of $^{68}$Ga whether in PBS or human serum (Figures 3(b) and 3(c)). The radiochemical purities of $[^{68}\text{Ga}]\text{Ga-NOTA-MAL-FSH1}$ were greater than 95% after 2h in vitro incubation (Table 1).

The partition coefficient (log $D$) of $[^{68}\text{Ga}]\text{Ga-NOTA-MAL-FSH1}$ was determined to be −3.12 ± 0.05.

3.3. Cell-Binding Assay. The binding of $[^{68/\text{nat}}\text{Ga}]\text{Ga-NOTA-MAL-FSH1}$ to the FSHR on PC-3 tumors was inhibited by various concentrations of nonlabeled FSH1, and the IC50 values were 123.7 ± 1.21 nM (Figure 4).

3.4. Cell Uptake. As shown in Figure 5, $[^{68}\text{Ga}]\text{Ga-NOTA-MAL-FSH1}$ uptakes in PC-3 cells were 1.10 ± 0.15, 1.39 ± 0.20, 1.51 ± 0.19, and 1.52 ± 0.21% AD for incubating at 15, 30, 60, and 120 min at 37°C, respectively. In the presence of blocking agent, the cell uptakes were significantly reduced to 0.30 ± 0.07% AD after incubating at 60 min, indicating the receptor targeting specificity of the probe.

3.5. MicroPET Imaging. Representative coronal MicroPET images of PC-3 tumor-bearing mice (n = 5 per group) at different times after intravenous injection of 3.7 MBq $[^{68}\text{Ga}]\text{Ga-NOTA-MAL-FSH1}$ are shown in Figure 6. PC-3 xenografts were visible with high tumor-to-background contrast. The tumor uptake of $[^{68}\text{Ga}]\text{Ga-NOTA-MAL-FSH1}$ was determined to be 1.87 ± 0.10, 1.26 ± 0.06, and 0.71 ± 0.10% ID/g at 30, 60, and 120 min (Table 2).

High activity accumulation was also observed in the kidney (21.10 ± 3.64% ID/g at 1 h p.i.) which indicated that $^{68}$Ga labeled peptide was mainly cleared via the urinary system. The in vivo FSHR binding property of $[^{68}\text{Ga}]\text{Ga-NOTA-MAL-FSH1}$ was also confirmed by blocking studies. Injection of a large excess of unlabeled FSH1 decreased PC-3 tumor uptakes to 0.31 ± 0.04% ID/g at 1 h postinjection.

3.6. Biodistribution Studies. The results of the biodistribution studies are summarized in Table 3. The tumor uptake of $[^{68}\text{Ga}]\text{Ga-NOTA-MAL-FSH1}$ was significantly higher than those in the blood and normal organs such as heart, liver, spleen, bone, muscle, and testis at 0.5 h, 1 h, and 2 h postinjection (p < 0.01). Due to longer retention of the tracer in tumor, the tumor to blood and tumor to muscle uptake ratios were 1.77 ± 0.70, 7.94 ± 1.35, and 10.37 ± 1.16 and 7.42 ± 0.46, 26.13 ± 2.99, and 36.40 ± 2.54, respectively.
Figure 6: In vivo PET imaging of PC-3 xenografted mice with $^{68}$Ga NOTA-MAL-FSH1. Decay-corrected whole-body coronal MicroPET images of PC-3 tumor bearing mice at 30, 60, and 120 min after injection of 3.7 MBq $^{68}$Ga NOTA-MAL-FSH1 without (a) and with (c) blocking dose. Tumors are indicated by arrows. Quantification of $^{68}$Ga NOTA-MAL-FSH1 in PC-3 tumor, liver, kidneys, and muscle without (b) and with (d) blocking dose. ROIs are shown as mean % ID/g ± SD.

| Uptake (% ID/g) | $^{68}$Ga NOTA-MAL-FSH1 | $^{68}$Ga NOTA-MAL-FSH1 block |
|-----------------|-------------------------|-----------------------------|
|                 | 0.5 h | 1 h | 2 h | 0.5 h | 1 h | 2 h |
| Tumor           | 1.87 ± 0.10 | 1.26 ± 0.06 | 0.71 ± 0.10 | 0.36 ± 0.08 | 0.31 ± 0.04 | 0.15 ± 0.03 |
| Muscle          | 0.25 ± 0.02 | 0.21 ± 0.04 | 0.13 ± 0.03 | 0.28 ± 0.09 | 0.24 ± 0.03 | 0.11 ± 0.01 |
| Liver           | 0.80 ± 0.07 | 0.44 ± 0.06 | 0.57 ± 0.12 | 0.23 ± 0.07 | 0.15 ± 0.03 | 0.12 ± 0.06 |
| Kidney          | 18.69 ± 3.44 | 21.10 ± 3.64 | 14.05 ± 2.76 | 15.27 ± 2.89 | 14.10 ± 3.01 | 13.78 ± 1.96 |
Table 3: Biodistribution of $^{68}$Ga-NOTA-MAL-FSH1 in PC-3 tumor bearing mice at various times after injection ($n = 5$).

| Parameter  | 30 min  | 60 min  | 120 min | 60 min block |
|------------|---------|---------|---------|--------------|
| % ID/g in  |         |         |         |              |
| Blood      | 0.95 ± 0.01 | 0.17 ± 0.02 | 0.13 ± 0.06 | 0.19 ± 0.30 |
| Brain      | 0.07 ± 0.01 | 0.03 ± 0.01 | 0.02 ± 0.01 | 0.03 ± 0.01 |
| Heart      | 0.35 ± 0.18 | 0.14 ± 0.05 | 0.05 ± 0.03 | 0.14 ± 0.05 |
| Liver      | 0.93 ± 0.28 | 0.56 ± 0.04 | 0.37 ± 0.05 | 0.12 ± 0.02 |
| Spleen     | 0.33 ± 0.03 | 0.26 ± 0.08 | 0.11 ± 0.05 | 0.15 ± 0.13 |
| Lung       | 0.67 ± 0.07 | 0.14 ± 0.01 | 0.10 ± 0.01 | 0.17 ± 0.05 |
| Kidney     | 24.98 ± 1.77 | 18.18 ± 2.81 | 13.91 ± 0.83 | 15.26 ± 1.20 |
| Stomach    | 0.40 ± 0.17 | 0.16 ± 0.06 | 0.04 ± 0.01 | 0.18 ± 0.08 |
| Intestine  | 0.32 ± 0.06 | 0.15 ± 0.03 | 0.05 ± 0.02 | 0.20 ± 0.02 |
| Muscle     | 0.26 ± 0.01 | 0.07 ± 0.01 | 0.04 ± 0.02 | 0.10 ± 0.02 |
| Pancreas   | 0.94 ± 0.13 | 0.11 ± 0.03 | 0.04 ± 0.02 | 0.19 ± 0.04 |
| Testis     | 0.24 ± 0.02 | 0.08 ± 0.01 | 0.03 ± 0.01 | 0.06 ± 0.00 |
| Fat        | 0.40 ± 0.01 | 0.13 ± 0.06 | 0.04 ± 0.00 | 0.17 ± 0.15 |
| Bone       | 0.34 ± 0.06 | 0.15 ± 0.07 | 0.06 ± 0.02 | 0.16 ± 0.07 |
| Tumor      | 1.97 ± 0.17 | 1.20 ± 0.27 | 0.97 ± 0.15 | 0.35 ± 0.12 |
| Ratio of tumor to |
| Blood      | 1.77 ± 0.70 | 7.94 ± 1.35 | 10.37 ± 1.16 | 1.54 ± 0.07 |
| Muscle     | 7.42 ± 0.46 | 26.13 ± 2.99 | 36.40 ± 2.54 | 1.95 ± 0.23 |
| Liver      | 2.67 ± 0.50 | 3.10 ± 0.40 | 2.84 ± 0.90 | 3.09 ± 0.24 |
| Intestine  | 6.68 ± 1.41 | 11.21 ± 2.42 | 14.17 ± 1.47 | 1.74 ± 0.09 |
| Kidney     | 0.07 ± 0.01 | 0.10 ± 0.02 | 0.06 ± 0.00 | 0.02 ± 0.01 |

Coinjection of excess FSH1 along with $^{68}$Ga-NOTA-MAL-FSH1 resulted in significantly reduced radioactivity accumulation in tumor from 1.20 ± 0.27% ID/g to 0.35 ± 0.12% ID/g at 1h postinjection.

4. Discussion

The recent introduction of $^{68}$Ga PET imaging into clinical practice represents a landmark in the ongoing developments in functional and metabolic imaging that is independent of the availability of a cyclotron [20]. Site-specific labeling is important as it provides chemically uniform radioconjugates with well-defined in vivo properties. Maleimide-NOTA is a NOTA-derivatized chelating system, which has specific reactivity toward thiol group [20]. In this study, NOTA-MAL was conjugated to the cysteine residue of FSH1 for site-specific labeling.

Previous studies have documented the overexpression of FSHR in human prostate cancer tissues, particularly in relation to hormone-resistant prostate tumors [9]. Human prostate cancer PC-3 is a hormone-resistant prostate tumor. Thus characteristics of $^{68}$Ga-NOTA-MAL-FSH1 were preliminary investigated in a PC-3 tumor model.

$^{68}$Ga-NOTA-MAL-FSH1 could be achieved in about 20 min through solid-phase extraction with satisfactory radiochemical purity. Our previous studies showed that the radiolabeling yields of $^{18}$FAl labeled FSH1 and its derivatives were 48.6 ± 2.1% and 41.46 ± 10.36% (nondecay-corrected), respectively, after 30 min preparation. After decay-corrected determination, the labeling yield of $^{18}$FAl labeled FSH1 and its derivatives was 58.6 ± 2.5% and 50.5 ± 11.2%, respectively. Compared with them, the decay-corrected labeling yield (~90%) of $^{68}$Ga-NOTA-MAL-FSH1 was significantly higher than those of $^{18}$FAl labeled counterparts [13, 14].

The radiolabeled NOTA-MAL-FSH1 was hydrophilic as indicated by the negative partition coefficients, which is similar to those of $^{18}$FAl labeled counterparts ($-3.12 ± 0.05$ versus $-3.05 ± 0.16$, resp.). $^{68}$Ga-NOTA-MAL-FSH1 showed in vitro stability in human serum and PBS for at least 2 hours. The IC50 values of displacement $^{68}$Ga-NOTA-MAL-FSH1 with FSHR antagonist, FSH1, were similar to $^{18}$FAl labeled counterparts, which primarily indicated the affinity of the tracer for FSHR was retained ($123$ nM versus $252$ nM, resp.). In vitro cell uptake assays also showed that coinubation with excess unlabeled FSH1 significantly blocked tumor uptake demonstrating the receptor binding specificity of the PET probe.

After labeling with $^{68}$Ga, we first performed MicroPET scans for $^{68}$Ga-NOTA-MAL-FSH1 in the PC-3 prostate xenograft model. The tracer showed prominent uptakes in the tumor compared with normal tissues such as heart, brain, muscle, and livers except kidneys. It was also noted that the uptake values in PC-3 xenografts were slightly lower than those of $^{18}$FAl labeled FSH1 ($1.26 ± 0.06$% ID/g versus $2.53 ± 0.20$% ID/g at 60 min p.i., resp., $p < 0.05$) [13]. The detailed mechanism was under investigation.

The results of the biodistribution study were consistent with the findings of PET imaging. It showed clear reduction of the radioactivity in the normal organs. The muscle uptakes...
of the probe were slightly lower than those of $^{18}$FAl-NOTA-MAL-FSH1 (0.07 ± 0.01 versus 0.15 ± 0.04% ID/g at 1 h p.i., resp.). The resulting tumor to muscle uptake ratio of the probe was more favorable than those of $^{18}$FAl labeled FSH1 peptides (26.13 ± 2.99 versus 16.17 ± 3.29 at 1 h p.i., resp.) [13]. It indicated that $^{68}$Ga labeled agent might be an alternative to $^{18}$FAl labeled compounds for PET imaging of FSHR expression where a cyclotron is of limited to access.

The FSHR specificity of $[^{68}\text{Ga}]$ Ga-NOTA-MAL-FSH1 was also confirmed by effective tumor uptake inhibition in the presence of excess FSH1 in both noninvasive PET imaging and biodistribution studies. The blocking study suggested that the tumor uptake of the tracer was specific to FSHR.

5. Conclusion

In summary, we have successfully developed a radiolabeled tracer, $[^{68}\text{Ga}]$ Ga-NOTA-MAL-FSH1 with high yield and purity. Preclinical data indicates that $[^{68}\text{Ga}]$ Ga-NOTA-MAL-FSH1 is promising for noninvasive visualization of FSHR expression in vivo. Further investigation of this novel radiotracer for detection of other FSHR tumor models such as breast and ovarian cancers is currently underway.

Conflicts of Interest

The authors declare no competing financial interests.

Authors’ Contributions

Guifeng Liu equally contributed to the work.

Acknowledgments

This work was partially supported by National Natural Science Foundation (81401450, 51477071, 81472749, 21504034, 21401084, and 31671035), Jiangsu Province Science and Technology Foundation (BE2014609, BE2016632, and BK20170204), and Jiangsu Provincial Medical Innovation Team (H201529 and Q201406).

References

[1] N. S. MacKlon and B. C. J. M. Fauser, "Follicle development during the normal menstrual cycle," Maturitas, vol. 30, no. 2, pp. 181–188, 1998.
[2] M. Simoni, J. Gromoll, and E. Nieschlag, "The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology," Endocrine Reviews, vol. 18, no. 6, pp. 739–773, 1997.
[3] B. Vannier, H. Loosfelt, G. Meduri, C. Pichon, and E. Milgrom, "Anti-human FSH receptor monoclonal antibodies: Immunochemo- and immunocytochemical characterization of the receptor," Biochemistry, vol. 35, no. 5, pp. 1358–1366, 1996.
[4] K. Papadimitriou, P. Kountourakis, A. E. Kottourou et al., "Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?" Molecular Diagnosis and Therapy, vol. 20, no. 6, pp. 523–530, 2016.
[5] A. Radu, C. Pichon, P. Camparo et al., "Expression of follicle-stimulating hormone receptor in tumor blood vessels," The New England Journal of Medicine, vol. 363, no. 17, pp. 1621–1630, 2010.
[6] M. A. Siraj, C. Pichon, A. Radu, and N. Ghinea, "Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib," Journal of Cellular and Molecular Medicine, vol. 16, no. 9, pp. 2010–2016, 2012.
[7] C. W. Lee, L. Guo, D. Matei, and K. Stantz, "Development of follicle-stimulating hormone receptor binding probes to image ovarian xenografts," Journal of Biotechnology & Biomaterials, vol. 05, no. 03, 2015.
[8] D. Yang, L. Feng, C. A. Dougherty et al., "In vivo targeting of metastatic breast cancer via tumor vasculature-specific nanographene oxide," Biomaterials, vol. 104, pp. 361–371, 2016.
[9] H. Hong, Y. Yan, S. Shi et al., "PET of follicle-stimulating hormone receptor: Broad applicability to cancer imaging," Molecular Pharmaceutics, vol. 12, no. 2, pp. 403–410, 2015.
[10] C. D. A. Ferreira, L. L. Fuschila, D. M. Townsend, D. Rubello, and A. L. B. D. Barros, "Radiolabeled bombesin derivatives for preclinical oncological imaging," Biomedicine and Pharmacotherapy, vol. 87, pp. 58–72, 2017.
[11] J. Shi, F. Wang, and S. Liu, "Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging," Biophysics Reports, vol. 2, no. 1, pp. 1–20, 2016.
[12] X. Sun, Y. Li, T. Liu, Z. Li, X. Zhang, and X. Chen, "Peptide-based imaging agents for cancer detection," Advanced Drug Delivery Reviews, 2016.
[13] L. Bodei, D. J. Kwekkeboom, M. Kidd, I. M. Modlin, and E. P. Krenning, "Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer," Seminars in Nuclear Medicine, vol. 46, no. 3, pp. 225–238, 2016.
[14] Y. Xu, D. Pan, C. Zhu et al., "Pilot study of a novel $^{18}$F-labeled FSHR probe for tumor imaging," Molecular Imaging and Biology, vol. 16, no. 4, pp. 578–585, 2014.
[15] C. Zhu, Q. Xu, D. Pan et al., "Prostate cancer imaging of FSHR antagonist modified with a hydrophilic linker," Contrast Media and Molecular Imaging, vol. 11, no. 2, pp. 99–105, 2016.
[16] L. Lang, W. Li, N. Guo et al., “Comparison study of $[18F]FAI-NOTA-PRGD2, $[18F] FPPRGD2, and $[68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice," Bioconjugate Chemistry, vol. 22, no. 12, pp. 2415–2422, 2011.
[17] I. Dijkstra, G. M. Franssen, W. J. McBride et al., "PET of tumors expressing gastrin-releasing peptide receptor with an $18$F-labeled bombesin analog," Journal of Nuclear Medicine, vol. 53, no. 6, pp. 947–952, 2012.
[18] D. O. Kiesewetter, N. Guo, J. Guo et al., “Evaluation of an $[18F]FAI-NOTA$-analog of exendin-4 for imaging of GLP-1 receptor in insulinoma,” Theranostics, vol. 2, no. 10, pp. 999–1009, 2012.
[19] G. Kramer-Marek, D. O. Kiesewetter, L. Martinova, E. Jagoda, S. B. Lee, and J. Capala, "[18F]FBEM-ZHER2:342-Affibody molecule - A new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography," European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 5, pp. 1008–1018, 2008.
[20] E. W. Price and C. Orvig, "Matching chelators to radiometals for radiopharmaceuticals," Chemical Society Reviews, vol. 43, no. 1, pp. 260–290, 2014.